This founder went from designing Happy Meal toys to making prosthetic skulls for a living—and her company now rakes in $20 million a year

MedCAD, a surgical solutions company founded in 2007, is a profitable entity leveraging 3D-printing technology for custom medical implants, including cranial, facial, foot, and ankle reconstruction. The company projects annual revenue between $10 million and $20 million for this year and 2026, driven by cranial and neuro products experiencing 18-25% year-over-year growth since 2022. MedCAD's revenue primarily derives from long-term contracts with global medical leaders, complemented by a ramping direct-to-hospital strategy, positioning it as a key innovator in the specialized 3D-printed medical implant market.

Analysis

MedCAD, a private surgical solutions company, demonstrates robust growth in the specialized 3D-printed medical implant market. The company projects annual revenues between $10 million and $20 million for both the current year and 2026, confirming its profitability. A significant growth driver is its cranial and neuro product line, which has experienced 18% to 25% year-over-year growth since 2022.

The company's revenue strategy primarily relies on long-term contracts with global medical leaders, complemented by an expanding direct-to-hospital sales approach. This dual strategy underscores its established market presence and efforts to broaden reach within the healthcare sector. MedCAD's innovative application of 3D modeling, initially developed in the toy industry, positions it as a key player in reconstructive surgery.

The strongly positive sentiment surrounding MedCAD highlights its impactful contributions to patient care through advanced technology. The founder's successful pivot from toy design to medical implants showcases a strategic vision for leveraging 3D printing in high-value healthcare applications. This trajectory suggests continued innovation and market penetration in a niche with significant unmet needs.

Key Decisions for Investors

• Given MedCAD's private status, direct investment is not feasible, but its growth signals a robust market for 3D-printed medical implants.
• Investors should monitor the broader medical technology sector for publicly traded companies specializing in or supplying to 3D-printed surgical solutions, especially those with strong growth in reconstructive applications.
• Consider companies with established long-term contracts in medical device supply or those expanding direct-to-hospital strategies, as these indicate strong market penetration and revenue stability.